WeVote
Log In

Bill

Bill

HB 117

relative to the substitution of biological products.

2025 Regular Session Introduced by Sue Prentiss and 1 co-sponsor

HB 117 regulates automatic substitution of biologic medications in New Hampshire, requiring notification and likely limiting interchangeable product switches to protect treatment continuity.

Signed by Governor Ayotte 07/15/2025; Chapter 163; eff. 09/13/2025 HJ 18
0
WeVote Research Nonpartisan
Bill Summary · HB 117

Legislative bill overview

HB 117 establishes rules for the substitution of biological products (biologics) in New Hampshire, likely requiring notification protocols or restrictions on automatic substitution of equivalent biologic medications. The bill became law on September 13, 2025, after Governor Ayotte's signature.

Why is this important

Biologic medications are complex, expensive drugs derived from living organisms used to treat conditions like rheumatoid arthritis, cancer, and autoimmune diseases. Uncontrolled substitution between different biologic manufacturers can raise clinical safety concerns and treatment continuity issues, making substitution rules a significant healthcare policy matter affecting patients, pharmacists, and insurers.

Potential points of contention

  • Patient access vs. cost control: Restrictions on biologic substitution may increase healthcare costs for insurers and patients while supporters argue it protects treatment efficacy and reduces adverse reactions
  • Pharmacist authority: The bill may limit pharmacists' traditional generic substitution authority, creating professional scope-of-practice conflicts between pharmacists and physicians
  • Industry interests: Biologic manufacturers and pharmacy benefit managers may have competing financial interests in substitution policies that aren't aligned with clinical outcomes

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.